Measuring retinal photoreceptor response to light stimulation

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This pilot study aims to develop a protocol for measuring changes in retinal photoreceptor layer thickness using a commercial optical coherence tomography (OCT) system before and after light stimulation. The study will investigate the feasibility of this method in healthy volunteers and patients with primary open-angle glaucoma and age-related macular degeneration. The research will also explore the influence of circadian processes on retinal responses. By utilizing newly developed algorithms, the study seeks to establish a reliable biomarker for photoreceptor function.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* men and women aged over 18 years
* signed informed consent form
* ametropia below 3 diopters
* ability and willingness to follow instructions

for healthy volunteers:

* normal ophthalmologic findings

for primary open angle glaucoma patients (POAG):

* diagnosed POAG
* MD \<= 10 dB

for age-related macular degeneration (AMD):

* diagnosed dry AMD
* diagnosed stage II or stage III AMD

Exclusion Criteria:

* Presence of any abnormalities preventing reliable measurements
* Ocular inflammation and ocular disease interfering with the study aims
* Use of photosensitizing medication (phototoxic drugs, photoallergic drugs) in the 3 months preceding the study
* Presence of any condition with the possibility of causing photosensitivity, including systemic lupus erythematosus SLE, Porphyria, Vitiligo, Xeroderma Pigmentosum and Albinism
* Presence of any form of epilepsy
* Ocular surgery in the 3 months preceding the study
* Pregnancy, planned pregnancy or lactating
* Any medical or surgical history, disorder or disease such as acute or chronic severe organic disease

Where it's running

• Medical University of Vienna, Department of Clinical Pharmacology
  Vienna, State of Vienna, Austria Recruiting

Study contacts

• Principal investigator: Doreen Schmidl, MD,PhD — Department of Clinical Pharmacology, Medical University of Vienna
• Study coordinator: Doreen Schmidl, MD,PhD
• Email: doreen.schmidl@meduniwien.ac.at
• Phone: 0043140400

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• G01 Eye Drops for Glaucomatous Optic Neuropathy

  This trial tests whether G01 Eye Drops can help people with open-angle glaucoma who also have optic nerve injury.

  Recruiting at 9 sites Phase 2 Qingdao WanMing BioCell Pharmaceutics Co.,Ltd. · Beijing, Beijing Municipality and 8 other locations · NCT07777861

• Additive Physical Activity for Hypothyroidism in Older Women with Glaucoma and Fatty Liver

  We’re testing whether adding a treadmill-based exercise program to standard thyroid treatment helps improve health in older women who have subclinical hypothyroidism, glaucoma, and fatty liver.

  Recruiting Cairo University · Dokki, Giza Governorate · NCT07599241

• Lifestyle changes plus nightly CPAP for glaucoma in people with sleep apnea

  This test checks whether adding a low-calorie diet and regular walking to nightly CPAP lowers eye pressure in people with high‑pressure open‑angle glaucoma who also have obstructive sleep apnea and obesity.

  Recruiting Cairo University · Giza, Dokki · NCT07447011

• Direct Selective Laser Trabeculoplasty to reduce glaucoma medications

  This study will try Direct Selective Laser Trabeculoplasty (DSLT) to reduce the number of eye-drop medications in adults with medically controlled primary open-angle glaucoma or ocular hypertension.

  Recruiting The Eye Institute of West Florida · Largo, Florida · NCT07390890

• Hexiris MIST device to lower eye pressure in people with primary open-angle glaucoma

  This trial will test the Hexiris MIST device to see if it lowers eye pressure in adults 40 and older whose primary open-angle glaucoma isn’t controlled by eye drops.

  Recruiting at 5 sites Hexiris Inc · Dieppe, New Brunswick and 4 other locations · NCT07358650

• PRESERFLO MicroShunt XI: patient experience follow-up after implantation for open-angle glaucoma

  A single-arm, post-market follow-up study to see how the PRESERFLO MicroShunt XI performs and whether it remains safe in adults with primary open angle glaucoma who aren’t controlled on medications.

  Recruiting at 10 sites Santen SAS · Vienna and 11 other locations · NCT07235592

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.